Antipsychotic polypharmacy among schizophrenia outpatients

被引：0
|
作者：
Maatallah, H. [1 ]
Ben Ammar, H. [1 ]
Aissa, A. [1 ]
Nefzi, R. [1 ]
Said, M. [1 ]
El Hechmi, Z. [1 ]
机构：
[1] Razi Hosp, Psy F, Tunis, Tunisia
来源：
EUROPEAN PSYCHIATRY | 2017年 / 41卷
关键词：
D O I：
10.1016/j.eurpsy.2017.01.1601
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EV1271
引用
收藏
页码：S821 / S821
页数：1
相关论文
共 50 条
  • [41] Gender differences in response to antipsychotic treatment in outpatients with schizophrenia
    Usall, Judith
    Suarez, David
    Haro, Josep Maria
    PSYCHIATRY RESEARCH, 2007, 153 (03) : 225 - 231
  • [42] Sexual dysfunction in antipsychotic-treated outpatients with schizophrenia
    Olfson, M
    Guardino, C
    Connolly, S
    Tafesse, E
    Carson, W
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S427 - S427
  • [43] Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
    Ijaz, Sharea
    Bolea, Blanca
    Davies, Simon
    Savovic, Jelena
    Richards, Alison
    Sullivan, Sarah
    Moran, Paul
    BMC PSYCHIATRY, 2018, 18
  • [44] Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Haya Ascher-Svanum
    Baojin Zhu
    Christoph Correll
    John Kane
    BMC Psychiatry, 5
  • [45] NO EFFECTS OF POLYPHARMACY AND ANTIPSYCHOTIC DOSE ON SPATIAL WORKING MEMORY IN SCHIZOPHRENIA
    Kleisas, S.
    Theochari, E.
    Andreopoulou, A.
    Kalogerakou, S.
    Psaras, R.
    Karouzos, C.
    Tsaltas, E.
    Kontis, D.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [46] Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program
    Tang, Yan
    Horvitz-Lennon, Marcela
    Gellad, Walid F.
    Lave, Judith R.
    Chang, Chung-Chou H.
    Normand, Sharon-Lise
    Donohue, Julie M.
    PSYCHIATRIC SERVICES, 2017, 68 (06) : 579 - 586
  • [47] Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study
    Patrichi, Bogdan
    Tapoi, Cristiana
    Rogojin, Radu
    Bedreag, Irina
    Dumitrache, Anca
    Itu, Andreea
    Dragomir, Radu
    Buciuc, Adela-Georgiana
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
  • [48] Switching antipsychotic polypharmacy to monopharmacy in patients with schizophrenia - The Third Report
    Suzuki, T
    Watanabe, K
    Arai, T
    Hosogane, N
    Tanaka, K
    Oda, K
    Nomura, K
    Yagi, G
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S16 - S16
  • [49] Antipsychotic Polypharmacy in Inpatients with Schizophrenia in Asia (2001-2009)
    Xiang, Y. -T.
    Wang, C. -Y.
    Si, T. -M.
    Lee, E. H. M.
    He, Y. -L.
    Ungvari, G. S.
    Chiu, H. F. K.
    Yang, S. -Y.
    Chong, M. -Y.
    Tan, C. -H.
    Kua, E. -H.
    Fujii, S.
    Sim, K.
    Yong, K. H.
    Trivedi, J. K.
    Chung, E. -K.
    Udomratn, P.
    Chee, K. -Y.
    Sartorius, N.
    Shinfuku, N.
    PHARMACOPSYCHIATRY, 2012, 45 (01) : 7 - 12
  • [50] Effects of divalproex/antipsychotic polypharmacy of schizophrenia on adiposity and fasting lipids
    Haupt, D
    Flavin, KS
    Hessler, MJ
    Schweiger, JA
    Luber, A
    Fahnestock, PA
    Maeda, J
    Newcomer, JW
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 563 - 563
12345